908 Devices Expects Q1 Revenue From Cont. Ops. To Be At Least $11.5M Vs $7.4M Last Year, Reflecting Reported Growth Of About 55%

Benzinga · 04/15 11:17

At least 55% reported revenue growth from continuing operations compared to prior year

908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for safety and defense tech applications, today announced preliminary unaudited financial results for the quarter ended March 31, 2025.

Preliminary unaudited revenue from continuing operations for the first quarter of 2025 is expected to be at least $11.5 million, compared to $7.4 million of revenue from continuing operations in the first quarter of 2024, reflecting reported growth of approximately 55%. First quarter revenues do not include approximately $1.1 million of additional revenue related to the desktop portfolio, that was divested on March 4, 2025, and will be reflected within the results of discontinued operations in the first quarter of 2025.

Cash, cash equivalents, and marketable securities were approximately $124 million (unaudited) at the end of the quarter, with an additional $4.0 million of cash held in escrow related to the divestiture of the desktop product portfolio. This amount does not include approximately $2.5 million of cash outflows related to transaction expenses to be paid in April 2025.

"Having divested our desktop portfolio in Q1, our team is now fully focused on executing our advanced chemical detection strategy, delivering strong revenue growth in the quarter, both domestically and internationally," said Kevin J. Knopp, CEO and Co-founder. "We are on track and remain committed to our goal of reaching Adjusted EBITDA positivity by the fourth quarter 2025."